Navigation Links
Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/18/2009

SEATTLE, May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced upcoming presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida. Abstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are now available to the public online at the ASCO Web site, www.abstract.asco.org.

    Abstracts include:

    -   "Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients
        (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)"

        - Abstract No: 3055 Poster session: Developmental Therapeutics:
        Immunotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2,
        West Hall C

    -   "Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K)
        inhibitor"

        - Abstract No: 3542 Poster session: Developmental Therapeutics:
        Molecular Therapeutics - Saturday May 30, 8:00 AM to 12:00 PM
        Level 2, West Hall C

    -   "Results from phase Ib studies of PX-12, a thioredoxin inhibitor in
        patients with advanced solid malignancies"

        - Abstract # 2571, Poster Session: Developmental Therapeutics:
        Cytotoxic Chemotherapy - Saturday May 30, 8:00 AM to 12:00 PM,
        Level 2, West Hall C

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forwa
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 9 Kendle (Nasdaq: KNDL ), ... announced Chief Operating Officer Christopher Bergen will participate ... March 10 as well as the Raymond James ... http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ) Barclays ...
... Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged ... announced that the U.S. Food and Drug Administration (FDA) ... Adhesion Barrier for use in pediatric cardiac surgery patients. ... over the surface of the heart at the conclusion ...
... Alliance, the leading management consulting firm specializing in ... Joe Dillon has joined its Business Development Practice. ... Business Development Practice to help pharmaceutical and biotech ... related to in- and out-licensing, opportunity assessment, and ...
Cached Biology Technology:Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 3Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3
(Date:7/10/2014)... of Manchester are a step closer to understanding why diabetes ... bypass surgery. , The research, published in the journal ... by the actions of specialised cells in the intestine that ... , During the research, the team showed that gut ... up to six hormones including the hunger hormone ghrelin. ...
(Date:7/10/2014)... whole fresh avocado with either an orange-colored tomato sauce ... and beta-carotene) absorption and conversion of these carotenoids to ... research (1) published in The Journal of ... involved in reproductive health and growth promotion; helps support ... properties. Provitamin A carotenoids, like alpha- and beta-carotene, impart ...
(Date:7/10/2014)... chronic inflammatory skin diseases psoriasis* and eczema** are similar ... to base their decision on which treatment should be ... tissue samples. A team of researchers at the Helmholtz ... have now analyzed the molecular processes that occur in ... them for the first time to gain a detailed ...
Breaking Biology News(10 mins):Scientists discover clues why weight-loss surgery cures diabetes 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New diagnostic test to distinguish psoriasis from eczema 2
... long believed that bigger is better when it comes to ... dinosaurs, have evolved into larger species over time. , ... the University of California, San Diego in an early online ... suggests that maxim, known as "Cope's Rule," may be only ...
... have discovered that butterflies experience a great loss in ... findings appear in the March issue of the Journal ... Molecular Biology journal. , "The transformation of a caterpillar ... says William E. Connor of the Oregon Health and ...
... February 15th issue of Genes & Development lends novel ... while they reside in the female reproductive tract ?providing ... fertilization. , It had been believed for decades that ... Haim Breitbart (Bar-Ilan University, Israel) now show that, in ...
Cached Biology News:Study finds evolution doesn't always favor bigger animals 2Study finds evolution doesn't always favor bigger animals 3Butterflies lose body fat during metamorphosis 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
... cell culture systems provide an integrated ... staining and imaging. Each system uses ... optical-quality coverslips in cell culture plates. ... and ready to use. Individual chambered ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
Biology Products: